Symbol="PRLD"
AssetType="Common Stock"
Name="Prelude TherapeuticsÂ Inc"
Description="Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized to target key drivers in cancers. The company is headquartered in Wilmington, Delaware."
CIK="1678660"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="200 POWDER MILL ROAD, WILMINGTON, DE, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="192498000"
EBITDA="-124046000"
PERatio="None"
PEGRatio="None"
BookValue="4.781"
DividendPerShare="0"
DividendYield="0"
EPS="-2.35"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.29"
ReturnOnEquityTTM="-0.464"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-2.35"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="9.6"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="1.145"
EVToRevenue="-"
EVToEBITDA="-0.214"
Beta="0.328"
num_52WeekHigh="8.9"
num_52WeekLow="3.5"
num_50DayMovingAverage="4.81"
num_200DayMovingAverage="5.9"
SharesOutstanding="39601500"
DividendDate="None"
ExDividendDate="None"
symbol="PRLD"
open="3.71"
high="3.80"
low="3.54"
price="3.67"
volume="59981.00"
latest_trading_day="2023-08-04"
previous_close="3.61"
change="0.06"
change_percent="1.6620%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="54"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="46"
Volume_recent_avg="113118"
Change_recent_avg="-0.02"
Delta_recent_avg="0.49"
Variance_recent_avg="0.24"
Change_ratio_recent_avg="-0.52"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="46"
Aroon_momentum_negative="54"
image_negative_thumbnail_id_1="1126"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0159.jpeg"
image_negative_thumbnail_id_2="125"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0051.jpeg"
image_neutral_thumbnail_id_1="559"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0040.jpeg"
image_neutral_thumbnail_id_2="595"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0004.jpeg"
image_positive_thumbnail_id_1="977"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0139.jpeg"
image_positive_thumbnail_id_2="612"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0096.jpeg"
image_professor_thumbnail_id_1="1171"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0005.jpeg"
image_professor_thumbnail_id_2="1199"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0033.jpeg"
